Patient satisfaction with tildrakizumab treatment in a Phase 4 real-world study of tildrakizumab in patients with moderate-to-severe psoriasis

被引：0
|
作者：
Bhatia, Neal [1 ]
Vasquez, J. Gabriel [2 ]
Schenkel, Brad [3 ]
Rozzo, Stephen J. [3 ]
Heim, Jayme [2 ]
机构：
[1] Therapeut Clin Res, San Diego, CA USA
[2] West Michigan Dermatol, Grandville, MI USA
[3] Sun Pharmaceut Ind Inc, Princeton, NJ USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2023年 / 89卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
42281
引用
收藏
页码：AB72 / AB72
页数：1
相关论文
共 50 条
  • [41] Real-world data on the use of secukinumab as treatment for moderate-to-severe psoriasis in Chinese patients
    Huang, He
    Cai, Ming-Long
    Hong, Xiao-Jie
    Zheng, Li-Jun
    Hu, Zhu-Lin
    Yuan, Tao
    Li, Wei-Ran
    Sheng, Yu-Jun
    Zhang, Xue-Jun
    EUROPEAN JOURNAL OF DERMATOLOGY, 2020, 30 (05) : 554 - 560
  • [42] Real-world data on the use of secukinumab as treatment for moderate-to-severe psoriasis in Chinese patients
    He Huang
    Ming-Long Cai
    Xiao-Jie Hong
    Li-Jun Zheng
    Zhu-Lin Hu
    Tao Yuan
    Wei-Ran Li
    Yu-Jun Sheng
    Xue-Jun Zhang
    European Journal of Dermatology, 2020, 30 : 554 - 560
  • [43] Ixekizumab treatment in patients with moderate-to-severe plaque psoriasis in a real-world clinical setting
    Ogut, Neslihan Demirel
    Yildirim, Sema Koc
    Erbagci, Ece
    Hapa, Fatma Asli
    JOURNAL OF COSMETIC DERMATOLOGY, 2022, 21 (11) : 6215 - 6224
  • [44] PSORIASIS-RELATED WORK PRODUCTIVITY IMPROVEMENT FROM A PHASE 4 REAL-WORLD STUDY INTERIM ANALYSIS OF TILDRAKIZUMAB
    Bhatia, N.
    Heim, J.
    Beute, P.
    Torres, M.
    Schenkel, B.
    Rozzo, S. J.
    Vasquez, J. G.
    VALUE IN HEALTH, 2022, 25 (07) : S390 - S391
  • [45] Real-world evidence of oral roflumilast in patients with moderate-to-severe psoriasis
    Gyldenlove, Mette
    Nissen, Christoffer Valdemar
    Stave, Sascha Dinsen Wreschner
    Thomsen, Simon Francis
    Egeberg, Alexander
    Loft, Nikolai
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
  • [46] Patient-reported outcomes and physician's satisfaction after 28 weeks of treatment with tildrakizumab in moderate-to-severe plaque psoriasis: interim analysis of the noninterventional study TILOT
    Tsianakas, A.
    Ostendorf, R.
    Diemert, S.
    Hinz, T.
    Pierchalla, P.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (01) : E40 - E40
  • [47] Tildrakizumab: An Evidence-Based Review of Its Use in the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis
    Naslund-Koch, Charlotte
    Zachariae, Claus
    Skov, Lone
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2020, 16 : 903 - 916
  • [48] BETTER SKIN CLEARANCE IS ASSOCIATED WITH IMPROVED QUALITY OF LIFE IN MODERATE-TO-SEVERE PSORIASIS PATIENTS TREATED WITH TILDRAKIZUMAB
    Blauvelt, Andrew
    Tyring, Stephen
    Gooderham, Melinda
    Koo, John
    Zhao, Yang
    Lowry, Simon
    Rozzo, Stephen
    Mendelsohn, Alan
    Parno, Jeffrey
    Reich, Kristian
    ACTA DERMATO-VENEREOLOGICA, 2018, 98 : 31 - 32
  • [49] EFFICACY OF TILDRAKIZUMAB IN MODERATE TO SEVERE PSORIASIS PATIENTS WITH PRIOR EXPOSURE TO APREMILAST
    Gordon, Kenneth
    Reich, Kristian
    Pariser, David
    Menter, Alan
    Tyring, Stephen
    Sofen, Howard
    Rozzo, Stephen
    Parno, Jeffrey
    Li, Qing
    La Rosa, Carmen
    ACTA DERMATO-VENEREOLOGICA, 2018, 98 : 29 - 30
  • [50] Clinical implications and predictive values of early PASI responses to tildrakizumab in patients with moderate-to-severe plaque psoriasis
    Feldman, Steven R.
    Merola, Joseph F.
    Pariser, David M.
    Zhang, Jingchuan
    Zhao, Yang
    Mendelsohn, Alan M.
    Gottlieb, Alice B.
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (03) : 1670 - 1675
12345